chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Amnesia, Aphasia, Cognitive disorder, Condition aggravated, Loss of personal independence in daily activities
Clinical narrative: tries to speak and can''t get words out; speech is getting worse; Tremors; jerking and shaking everywhere she goes; having problems remembering things; she can't think most times; she is afraid to even try and cook because she did one day and she almost set her house on fire; The caller explains she is progressively getting worse.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 66 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: APHASIA (non-serious), outcome "not recovered", described as "tries to speak and can''t get words out; speech is getting worse"; TREMOR (non-serious), outcome "not recovered", described as "Tremors; jerking and shaking everywhere she goes"; AMNESIA (non-serious), outcome "not recovered", described as "having problems remembering things"; COGNITIVE DISORDER (non-serious), outcome "not recovered", described as "she can't think most times"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious), outcome "not recovered", described as "she is afraid to even try and cook because she did one day and she almost set her house on fire"; CONDITION AGGRAVATED (non-serious), outcome "not recovered", described as "The caller explains she is progressively getting worse.". The events "tries to speak and can''t get words out; speech is getting worse", "tremors; jerking and shaking everywhere she goes", "having problems remembering things", "she can't think most times", "she is afraid to even try and cook because she did one day and she almost set her house on fire" and "the caller explains she is progressively getting worse." were evaluated at the physician office visit.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Tremor
Clinical narrative: tries to speak and can''t get words out; speech is getting worse; Tremors; jerking and shaking everywhere she goes; having problems remembering things; she can't think most times; she is afraid to even try and cook because she did one day and she almost set her house on fire; The caller explains she is progressively getting worse.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 66 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: APHASIA (non-serious), outcome "not recovered", described as "tries to speak and can''t get words out; speech is getting worse"; TREMOR (non-serious), outcome "not recovered", described as "Tremors; jerking and shaking everywhere she goes"; AMNESIA (non-serious), outcome "not recovered", described as "having problems remembering things"; COGNITIVE DISORDER (non-serious), outcome "not recovered", described as "she can't think most times"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious), outcome "not recovered", described as "she is afraid to even try and cook because she did one day and she almost set her house on fire"; CONDITION AGGRAVATED (non-serious), outcome "not recovered", described as "The caller explains she is progressively getting worse.". The events "tries to speak and can''t get words out; speech is getting worse", "tremors; jerking and shaking everywhere she goes", "having problems remembering things", "she can't think most times", "she is afraid to even try and cook because she did one day and she almost set her house on fire" and "the caller explains she is progressively getting worse." were evaluated at the physician office visit.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Cardiac disorder, Dizziness
Clinical narrative: It felt like an adrenaline boost to my heart; lightheadedness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CARDIAC DISORDER (non-serious), outcome "unknown", described as "It felt like an adrenaline boost to my heart"; DIZZINESS (non-serious), outcome "unknown", described as "lightheadedness".  Additional information: Patient was trying to understand the reaction to the COVID Vaccine. It felt like an adrenaline boost to his heart. It happened several times in the first 30 minutes, several times after that. And patient felt like his had times of lightheadedness for 1-2 weeks after the shot.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Cardiac disorder, Feeling abnormal, Heart rate, Heart rate increased, Palpitations
Clinical narrative: It felt like an adrenaline boost to my heart; lightheadedness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CARDIAC DISORDER (non-serious), outcome "unknown", described as "It felt like an adrenaline boost to my heart"; DIZZINESS (non-serious), outcome "unknown", described as "lightheadedness".  Additional information: Patient was trying to understand the reaction to the COVID Vaccine. It felt like an adrenaline boost to his heart. It happened several times in the first 30 minutes, several times after that. And patient felt like his had times of lightheadedness for 1-2 weeks after the shot.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: I broke out in very itchy rash all over my body - shin, area between my pelvic area and navel, knees, scalp and upper arms; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose), for COVID-19 immunization. The following information was reported: RASH (non-serious), outcome "unknown", described as "I broke out in very itchy rash all over my body - shin, area between my pelvic area and navel, knees, scalp and upper arms". Additional information: The patient reported After I received a second Pfizer shot in Jun, I broke out in very itchy rash all over my body -shin, area between my pelvic area and navel, knees, scalp and upper arms. The most severe rash appeared on my right shin in Jul. To this day, 07Feb2022, I am still dealing with most of these rashes even though I apply steroid prescribed by my doctor.  The lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
Age: 14.0
Sex: F
Vaccine: COVID19
Symptoms: Acne, Allergy to vaccine
Clinical narrative: had little pimples on her face; allergy/ allergy that her daughter had because of the Pfizer covid vaccine; This is a spontaneous report received from contactable reporter(s) (Consumer or other non-HCP). The reporter is the parent.  A 14-year-old female patient received bnt162b2 (BNT162B2), administered in arm, administration date 21Jan2022 (Batch/Lot number: unknown) at the age of 14 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: DESOGESTREL taken for dysmenorrhoea. The following information was reported: ACNE (non-serious) with onset 22Jan2022, outcome "recovering", described as "had little pimples on her face"; ALLERGY TO VACCINE (non-serious) with onset 22Jan2022, outcome "recovering", described as "allergy/ allergy that her daughter had because of the Pfizer covid vaccine". Therapeutic measures were taken as a result of acne, allergy to vaccine.  Additional information: The reporter stated that the patient had the reaction like she had little pimples on her face. This started the second day after the vaccine. This event happened for about 4 days and then the patient took Benadryl and then it improved. Also stated that an allergy that her daughter had because of the Pfizer covid vaccine.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Allergy to chemicals, Mycotic allergy
Clinical narrative: I had a chemical sensitivity & an allergy to mold.; I had a chemical sensitivity & an allergy to mold.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 20220127000915 (Sanofi).  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 05May2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "Cough" (unspecified if ongoing); "chest tightness" (unspecified if ongoing); "SOB" (unspecified if ongoing), notes: SOB. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose:1), for COVID-19 Immunization. The following information was reported: ALLERGY TO CHEMICALS (non-serious), MYCOTIC ALLERGY (non-serious) all with onset 15May2021, outcome "unknown" and all described as "I had a chemical sensitivity & an allergy to mold.".  Additional information: The patient had been taking DPXT since Jun2021 for asthma , reported over last month having cough, chest tightness and SOB and using my recue INH more than 2X/WK over the last month, its usually been better or about the same since taking DPXT but it has not got worse. The patient got the Pfizer Covid vaccine for 1st two doss and the Moderna vaccine for the booster in Dec2021 and it temporarily made him asthma symptoms worse. Ten days after 2nd Covid vaccine dose on 05May2021 the patient had chemical sensitivity and an allergy to mold  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.  Follow-up (14Mar2022): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Alanine aminotransferase increased, Anion gap, Aspartate aminotransferase, Basophil count, Blood albumin
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Blood alkaline phosphatase, Blood bilirubin, Blood calcium, Blood chloride, Blood cholesterol
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Blood creatine increased, Blood creatinine, Blood glucose, Blood glucose increased, Blood iron
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Blood potassium, Blood pressure measurement, Blood sodium, Blood thyroid stimulating hormone, Blood thyroid stimulating hormone increased
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Blood triglycerides, Blood urea, Carbon dioxide, Eosinophil count, Glomerular filtration rate
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Glycosylated haemoglobin increased, Haematocrit, Haemoglobin, High density lipoprotein, Iron binding capacity total
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Low density lipoprotein, Low density lipoprotein increased, Lymphocyte count, Mean cell haemoglobin, Mean cell haemoglobin concentration
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Mean cell volume, Mean platelet volume, Monocyte count, Neutrophil count, Non-high-density lipoprotein cholesterol
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Non-high-density lipoprotein cholesterol increased, Oxygen saturation, Platelet count, Protein total increased, Red blood cell count
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Red cell distribution width increased, SARS-CoV-2 test, Total cholesterol/HDL ratio, Transferrin saturation, Very low density lipoprotein
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: White blood cell count
Clinical narrative: Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl; Glucose=117 (H) / Ref Range: 70 - 99 mg/dl; Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl; LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl; TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 85 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 01Oct2021 (Lot number: 30145BA) at the age of 84 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "Psoriatic arthritis" (unspecified if ongoing); "Is the patient a smoker/former smoker? No" (unspecified if ongoing), notes: Is the patient a smoker/former smoker? No. Family history included: "vitiligo" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease.; "Raynaud's disease" (unspecified if ongoing), notes: my nice/both of my have vitiligo and Raynaud's disease. Concomitant medication(s) included: INDAPAMIDE taken for hypertension. Vaccination history included: Bnt162b2 (Dose-1, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EL3247, Route of administration: Intramuscular), administration date: 21Jan2021, when the patient was 84 years old, for COVID-19 Immunization; Bnt162b2 (Dose-2, Covid vaccine name: Pfizer, site of injection: Left upper arm, Lot: EM9809, Route of administration: Intramuscular), administration date: 12Feb2021, when the patient was 84 years old, for COVID-19 Immunization. The following information was reported: BLOOD CREATINE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Creatinine=0.82 (H) / Ref Range: 0.50 - 0.80 mg/dl"; BLOOD GLUCOSE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Glucose=117 (H) / Ref Range: 70 - 99 mg/dl"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "Non-HDL Cholesterol=141 (H) / Ref Range: 70 - 130 mg/dl"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "LDL Calculated=112 (H) / Ref Range: 40 - 100 mg/dl"; BLOOD THYROID STIMULATING HORMONE INCREASED (non-serious) with onset 07Feb2022, outcome "unknown", described as "TSH=5.135 (H) / Ref Range: 0.550 - 4.780 ulU/mL". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of blood creatine increased, blood glucose increased, non-high-density lipoprotein cholesterol increased, low density lipoprotein increased, blood thyroid stimulating hormone increased.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Cardiac disorder
Clinical narrative: said that he was recommended by "both cardiologists" he consulted, to not get the second dose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program.  A 55 year-old male patient received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CARDIAC DISORDER (non-serious), outcome "unknown", described as "said that he was recommended by "both cardiologists" he consulted, to not get the second dose".  The lot number for the vaccine, [BNT162B2] was not provided and will be requested during follow-up.  Follow-up (02Mar2022): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Migraine
Clinical narrative: migraine headaches; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 82 year-old female patient received bnt162b2 (BNT162B2), administration date 2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation; covid-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MIGRAINE (non-serious) with onset 2021, outcome "recovered", described as "migraine headaches".  Additional information: Reporter stated that her 82-year-old sister who got her first shot of the Pfizer Covid 19 vaccine experienced headaches and migraines for 6 months after taking the shot. Reporter then stated that her sister got the moderna shot for her second shot and experienced the same headaches / migraines. Reporter was asking if there was any information regarding these headaches. Again stated she took the first one and then started getting migraine headaches.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient. A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown , single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "painful arm". Additional information: Caller said he had the Pfizer COVID-19 vaccine also before and he only had a painful arm and no other symptoms. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.